Education
About Us
Working with TipRanks
Follow Us
Mark W. Frohlich Insider Profile
4 Followers
Mark W. Frohlich, EVP, Development & Portfolio Strategy at Juno Therapeutics, holds 1.25K shares in Rigel (Ticker: RIGL), holds 937.50K shares in Juno Therapeutics (Ticker: JUNO), holds 525.28K shares in Dendreon Corp (Ticker: DNDNQ).
Mark W. Frohlich Juno Therapeutics (JUNO)EVP, Development & Portfolio Strategy
Juno Therapeutics (JUNO)
EVP, Development & Portfolio Strategy
Ranked #72,595 out of 102,674 Corporate Insiders
Profitable Transactions
4 out of 13 Profitable Transactions
Average Return
-7.20%
Average return per transaction
Time Frame
Compare to
Insider Holdings
100.00%
A breakdown of Mark W. Frohlich's holdings
Insider Roles
Director
Roles that Mark W. Frohlich holds in companies
Most Profitable Insider Trade
Stock:
Dendreon Corp
(DNDNQ)
(DNDNQ)
Rating:Informative Sell
Date:Nov 14, 2011 - Nov 14, 2012
Return:+44.40%
The most profitable trade made by Mark W. Frohlich
Mark W. Frohlich's Trading History
Juno Therapeutics
Mar 02, 2016
―
Uninformative Sell
705.18K
$81.53M
Rigel
May 28, 2025
Director
Uninformative Buy
―
$27.39K
Dendreon Corp
Jan 22, 2014
―
Uninformative Sell
2.84K
―
List of latest transactions for each holding click on a transaction to see Mark W. Frohlich's performance on stock
You May Also Like
Mark W. Frohlich insider profile FAQ
What is the percentage of profitable transactions made by Mark W. Frohlich?
The percentage of profitable transactions made by Mark W. Frohlich is 31%.
What is the average return per transaction made by Mark W. Frohlich?
The average return per transaction made by Mark W. Frohlich is -7.20%.
What stocks does Mark W. Frohlich hold?
Mark W. Frohlich holds: JUNO, RIGL, DNDNQ stocks.
What was Mark W. Frohlich’s latest transaction?
Mark W. Frohlich latest transaction was an Uninformative Buy of ―.
What was Mark W. Frohlich's most profitable transaction?
Mark W. Frohlich’s most profitable transaction was an Informative Sell of DNDNQ stock on November 14, 2011. The return on the trade was 44.40%.
What is Mark W. Frohlich's role in Juno Therapeutics?
Mark W. Frohlich's role in Juno Therapeutics is EVP, Development & Portfolio Strategy.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.